Dyne a new overweight at Cantor on platform for neuromuscular disorders
Seeking Alpha ·
Cantor Fitzgerald has initiated Dyne Therapeutics (DYNE) at outperform, finding significant value in its FORCE platform to treat rare genetic muscle disease. Analyst Eric Schmidt said that the company's lead asset , the Duchenne muscular dystrophy treatment zeleciment rostudirsen (z-rostudirsen), is likely
DYAX Investor Sentiment
Bullish (Long) 39% · Bearish (Short) 61%
331 participants
Related News
- Eurazeo SE reports 1H results
- Laboratorios Farmaceuticos Rovi, S.A. reports 1H results
- AlphaSense mulls initial public offering - The Information
- Armour Residential REIT outlines range-bound spreads while maintaining $0.24 monthly dividend and growing assets above $22b
- Royal Caribbean courts Mexican government with community center in Mahahual
- Drone makers develop GPS alternatives as electronic warfare reshapes battlefield
